All In Biotech

Drug Trial Radar · NCT05340621

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

NAUTILUS: a Phase 1b/2 Study of OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1b) and in Patients with Advanced NRAS-Mutated Melanoma (Phase 2)

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

May 11, 2022

Primary completion

Jan 29, 2025

Study completion Jan 29, 2025

Sponsor

Lead sponsor
OnKure, Inc.Industry
Sponsor type
Industry
First posted
Apr 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.

Conditions

  • RAS Mutation
  • NRAS Gene Mutation
  • Melanoma

Interventions

  • OKI-179 + binimetinibDrug

    Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously. Phase 2: Patients will be treated with the RP2D.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Incidence and severity of dose-limiting toxicities (DLTs)Time frame: First 28 days of treatment
  2. Phase 1b: Incidence and severity of adverse events (AEs)Time frame: Phase 1b study duration (approximately 1.5 years)
  3. Phase 1b: Change in clinical laboratory abnormalitiesTime frame: Baseline through 30 days after end of study treatment
  4. Phase 1b: Change in Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Phase 1b study duration (approximately 1.5 years)
  5. Phase 2: Objective response rate (ORR)Time frame: Phase 2 study duration (approximately 3 years)

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • CTCA Phoenix, part of City of Hope

    Phoenix, Arizona

  • University of California, San Francisco

    San Francisco, California

  • University of Florida Health Cancer Center

    Gainesville, Florida

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • CTCA Atlanta, part of City of Hope

    Newnan, Georgia

  • CTCA Chicago, part of City of Hope

    Zion, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.